29.03.2012 - Promethera Biosciences has completed a Series B financing round, generating proceeds of €23.6m.
The Belgian cell therapy company secured a capital increase of €17m from its new investors, among them the venture arms of pharmaceutical industry leaders Boehringer Ingelheim and Shire, Japanese investment fund Mitsui Global Investment, US company ATMI and Belgian venture capital fund SambrInvest. In addition, the Walloon Region, which has backed the project since its inception, has granted a loan of €6.6m to support the clinical development of Promethera’s liver disease treatment HepaStem. The deal comes only a little over two years after the first financing round, which raised €5.3m. "Achieving all our objectives a year ahead of plan and the proof of concept obtained in humans have been key factors in our investors' decision”, said Eric Halioua, CEO of Promethera Biosciences. Heterologous Human Adult Liver Progenitor Cells (HHALPC) form the basis for the liver disease treatment HepaStem.
The proof of concept for the therapeutic use of the cells has been demonstrated in three different animal models. Between 2009 and 2011, injections of HHALPC were safely administered to three patients - a world first - at Cliniques Universitaires St Luc by Professor Sokal and his team. These various achievements have enabled Promethera Biosciences to obtain the first authorisations from the British (MHRA) and Belgian (AFMPS) regulatory authorities to begin the phase I/II clinical study of HepaStem. The patent protecting the HHALPC cell and all of its applications has been officially awarded in Europe. “We believe that Promethera HepaStem has, even though early in development, significant potential to treat metabolic liver diseases and we are looking forward to working with the company now and in the future,” commented Dr. Ilka Wicke, director at the Boehringer Ingelheim Venture fund.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.